We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pharmascience has launched in Canada Prpms-TRANDOLAPRIL (angiotensin-converting enzyme inhibitor), indicated for the treatment of mild to moderate essential hypertension and the treatment following acute myocardial infarction.